2014 Fiscal Year Final Research Report
Development of novel HDAC/PI3K dual inhibitors
| Project/Area Number |
25830110
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
SAIJO KEN 東北大学, 大学病院, 助教 (70636729)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Keywords | 分子標的薬 / 創薬 / HDAC阻害剤 / PI3K阻害剤 |
|---|
| Outline of Final Research Achievements |
Both HDAC and PI3K are considered to be promising targets for cancer therapy. A combination of an HDAC inhibitor and a PI3K inhibitor potentiates the cytotoxic effect in a synergistic manner. Therefore, development of an HDAC/PI3K dual inhibitor will provide an attractive novel drug. The depsipeptide analogs have been identified as HDAC/PI3K dual inhibitors. Moreover, using structure based optimization, FK-A11 has been identified as the most potent analog. FK-A11 showed anti-tumor effects in vivo mouse model using human prostate cancer cells.
|
| Free Research Field |
臨床腫瘍学
|
